Vitamin D 3 is a promising preventative and therapeutic agent for prostate cancer, but its implementation is hampered by a lack of understanding about its mechanism of action. These studies establish a system to study the molecular profile of PrP/SC differentiation, proliferation, and senescence, and they point to an important new role for IL1in vitamin D 3 signaling in prostate progenitor/stem cells.
Introduction
Prostate cancer is the second-deadliest non-cutaneous cancer in US men, accounting for an estimated 32,050 deaths in 2010 (1) . The factors that lead to prostate cancer development and progression are poorly understood. Epidemiological, genetic, and epigenetic studies contribute to the idea that prostate cancer development and progression is associated with vitamin D 3 deficiency. Clinical studies correlating circulating serum levels of 25 hydroxyvitamin D 3 (25(OH)D 3 ) and prostate cancer incidence have been inconclusive (2) . However, epidemiological and laboratory studies collectively point to a role for 1,25 dihydroxyvitamin D 3 (1, 25(OH) 2 (11) . In addition, 1,25(OH) 2 D 3 -induced differentiation of prostate cells is characterized by increased levels of prostate-specific antigen (PSA), kallikrein 2, E-cadherin, and androgen receptor (AR) (10, (12) (13) (14) . Pieces of the complex molecular mechanisms behind 1,25(OH) 2 D 3 signaling in the cells of the prostate are starting to be identified, and we aim to add to this growing knowledge.
Recent studies including our own have identified putative adult prostate stem cells that undergo self-renewal and multilineage differentiation into the epithelial cell types of the prostate (15) (16) (17) (18) (19) . The phenotypic attributes in common between normal stem cells and tumor cells as well as the presence in the tumor of mutations in signaling pathways important for normal stem cell self-renewal have led to the hypothesis that normal stem cells may be the target of mutagenesis leading to tumor formation (20) . A major goal in prostate stem cell biology is to identify genes, pathways, and networks that control self-4 renewal and multilineage differentiation. Studies in this direction have been hampered by a lack of suitable models that allow for long-term maintenance of a stem cell population. Here, we present an in vitro system that overcomes these barriers and provides a model for studying the molecular profile of prostate stem cell differentiation induced by 1,25(OH) 2 D 3 .
In accordance with the prostate cancer stem cell hypothesis, we believe that the prostate progenitor/stem cell (PrP/SC) is the most relevant target for chemoprevention. The PrP/SC has a nearly unlimited replicative capacity, but it can respond robustly to differentiation cues to enter a stage of limited or no replicative capacity. Agents that promote PrP/SC differentiation and limit replicative capacity are strong candidates for the development of a mechanism-based chemoprevention strategy for prostate cancer (21) . We have confirmed the endogenous expression of 1- hydroxylase (1OHase), the activating enzyme that converts 25(OH)D 3 to 1,25(OH) 2 D 3 , in PrP/SC by reverse-transcriptase PCR (Fig.   S1 ), which supports our hypothesis that the PrP/SC is a suitable model for studying the mechanistic response to vitamin D. We hypothesize that 1,25(OH) 2 D 3 regulates differentiation of PrP/SC, and we believe that the effects of 1,25(OH) 2 D 3 on the normal stem cell has significant implications for the functional role of vitamin D 3 as a chemopreventative agent.
Materials and Methods

Culture of mouse prostatic progenitor/stem cells
Adult mouse prostate progenitor/stem cells were isolated and maintained as described in (15) and (22) .
Experiments were performed between passages 20 and 30. 
Antibodies and reagents
Antibodies
Isolation of VDR null mouse prostatic epithelial cells
Animals were bred and MPECs were isolated as described previously (22) . VDR knockout was confirmed using reverse-transcriptase PCR (New England Biolabs). 
Flow Cytometry
Immunoblotting
Procedures for immunoblotting protein lysates from cells grown in monolayer is described in detail elsewhere (22) . 
Microarray experiments
Growth assays
Trypan blue exclusion assays were performed as described in (8) .
Clonogenic assays
Clonogenic assays were performed as described in (15) .
Quantitative real-time PCR analysis
RNA was isolated in triplicate from PrP/SC cells treated with vehicle (0.1% ethanol) or 100 nM 1,25(OH) 2 D 3 for 24 hr, quantified and converted to cDNA using reverse transcriptase and diluted 1:10 in H 2 O. qPCR was performed using Bio-Rad iQ SYBR green super-mix. The results were analyzed using delta-delta Ct calculations and normalized to the control (error bars show the standard deviations).
Statistical significance was determined by T-test (critical value = 0.05), n = 3. Primer sequences are available upon request.
shRNA targeting
shRNA vectors were generated as described in Sui and Shi (28). The IL1target sites are GGTAGTGAGACCGACCTCATT (shRNA1) and GACTGCCCTCTATGACAGACTT (shRNA2).
After infection with ecotropic virus, single cell clones were generated using cloning cylinders, and the 
Enzyme-linked immunosorbant assay (ELISA)
ELISA was performed according to the manufacturer's instructions in a kit from R&D Systems (catalog number MLA00).
Immunofluorescence
Immunofluorescence was performed as described in (29). Fluorescent signal images were captured using a Nikon DXM1200F digital camera on a Nikon Eclipse 50i microscope with an EXFO X-Cite 120
Fluorescence Illumination System.
Senescence-associated beta-galactosidase (SA-β-gal) assay
SA-β-gal activity was evaluated as described in Axanova et al.(30) .
Results
1,25-dihydroxyvitamin D 3 induces cell cycle arrest and senescence in PrP/SC.
We first characterized the phenotypic effects of 1,25(OH) 2 D 3 on proliferation and cell cycle progression in prostate progenitor/stem cells that were isolated and maintained in our lab (15, 22) . p21 and p27 impact G1/S cell cycle progression by inhibiting Cyclin E/Cdk2 kinase activation. A major downstream target of Cdk2 that regulates G1/S progression is pRb. However, it is becoming increasingly clear that other targets of Cdk2, such as proteins involved in replication, are also important (6) . To test the necessity of pRb in the 1,25(OH) 2 D 3 -mediated anti-proliferative response, we deleted exon 19 of the pRb locus (15) . We previously reported the isolation and characterization of PrP/SC from pRb loxP/loxP animals (15, 22) . These cells were infected in vitro with adenoviral Cre recombinase and validated for loss of pRb by immunoblot (Fig. S2) (Fig. 1D) .
We next analyzed cell cycle progression in asynchronously-dividing wild-type (WT) PrP/SC, (Table S6) . Figure 2A , 100 nM 1,25(OH) 2 D 3 induced global regulation of genes involved in cell cycle progression (Fig. 3A) . These include genes encoding proteins important for G1/S progression such as cyclin E2, Cks1b, Pcna, and multiple members of the E2F family of transcription factors. There was also regulation of genes involved in DNA synthesis and replication fork loading such as Cdc7, Orc2l, and Mcm6. corresponding proteins of which directly contribute to or modulate spindle assembly and mitosis (Fig.   3A) . Interestingly, neither p21 nor p27 were present in the gene lists at 6 hr, which is consistent with other studies in our laboratory that suggest that these proteins are regulated as secondary targets of 1,25(OH) 2 D 3 in prostate cells (Tables S1-S4) (7, 8) . Most notable among differentiation targets are androgen receptor (AR) and prostatic acid phosphatase (Acpp), which are both increased by 6 hr and exhibit further increases at 48 hr of 1,25(OH) 2 We confirmed a sample set of gene targets from the microarray results by qPCR including AR, prostatic acid phosphatase (Acpp), kallikrein 26 (Klk26), keratin 4 (Krt4), prostate stem cell antigen (Psca), stefin A1 (Stfa1), bone morphogenetic protein 4 (Bmp4), and bone morphogenetic protein receptor 1A (Bmpr1a) (Fig. 3B) . Prostate stem cell antigen is a misnomer for this gene/protein; Psca expression in the prostate stem cell is low, but levels increase when the cell undergoes differentiation into a transit amplifying cell (37) . The increase in Psca in response to 1,25(OH) 2 D 3 supports the hypothesis that 1,25(OH) 2 D 3 drives differentiation of the PrP/SC into a transit amplifying cell. The other targets such as AR, Acpp, keratins, and kallikreins suggest that the transit amplifying cell population is progressing toward a luminal cell phenotype. We believe that this in vitro differentiation model will allow for in-depth analysis of the molecular programming behind PrP/SC differentiation.
Consistent with the cell cycle analysis in
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Interleukin-1 alpha is a novel target for 1,25(OH) 2 D 3 signaling in PrP/SC
Our goal is to identify key pathways governing vitamin D 3 -mediated effects so that we may better design rational combinatorial strategies for prostate cancer chemoprevention. While the array data were informative, it was not clear which target(s) should be pursued based solely on fold induction; a systems biology approach was needed in order to make more informed decisions. To do this, we evaluated the microarray data using the Ingenuity Pathway Analysis (IPA) program suite, which identifies regulated networks based on signaling pathways, protein-gene and protein-protein interactions, biological functions, and diseases. Normalized and statistically significant array data were evaluated by IPA, and networks were generated using protocols provided with the software. Figure 4 shows the top-scoring network of (Fig. S3B) . The Affymetrix array data showed that IL1 was upregulated 6.8-fold at 6 hr and 4.8-fold at 48 hr (Tables S1 and S3 ). In addition, numerous previouslydefined targets of IL1 signaling such as Mmp13, Cox2, and Nfkbiz were upregulated at the 48 hr timepoint in the array data, suggesting that these are secondary targets of 1,25(OH) 2 D 3 signaling mediated by IL1 (Fig. S4 and Table S3 ). induced IL1 protein (33 kDa) and mRNA levels within 6 hr, and levels peaked at 24 hr of treatment in PrP/SC (Fig. 5A and 5B) . We also saw induction of IL1by 100 nM 1,25(OH) 2 D 3 in additional PrP/SC strains with different genetic backgrounds (Fig. S5) (Fig. 5C) .
Since IL1secretion was negligible, we used immunofluorescence to visualize IL1localization. IL1 appeared to reside in the cytoplasmic and nuclear compartments of PrP/SC upon treatment with 1,25(OH) 2 D 3 (Fig. 6) . Additionally, Western blots did not detect a 17 kDa band for the membraneassociated form of IL1. Together, this suggests that IL1 acts in a primarily intracellular (and not membrane-bound) manner in PrP/SC, consistent with arguments for intracrine actions of IL1 (38).
However, high dose exogenous IL1 100 ng/ml) elicited a 40% growth inhibition (Fig. S6) , suggesting the potential for receptor-mediated signaling to contribute to the observed effects.
To evaluate the role of IL1 in the anti-proliferative effects of 1,25(OH) 2 D 3 , we developed shRNA vectors that target IL1 and a control vector. We verified by Western blot that IL1 expression was suppressed by the targeted shRNAs ( Fig. 7A and B) . We also verified that shRNA-infected cells maintained an intact VDR signaling pathway by assessment of Cyp24a1 mRNA expression (Fig. S7) . ) with control and IL1 shRNA1 (Fig. S8A) . Treatment with 1,25(OH) 2 D 3 validated our findings that IL1 was necessary for the antiproliferative effects of 1,25(OH) 2 D 3 in the PrP/SC (Fig. S8B) . To test whether IL1is sufficient to restore growth inhibition by 1,25(OH) 2 D 3 , we treated IL1shRNA-infected PrP/SC with a range of dose combinations of exogenous IL1and 1,25(OH) 2 D 3 (Fig. S9) . 10 ng/mL IL1 was sufficient to rescue 1,25(OH) 2 D 3 -mediated growth suppression (Fig. 7C) . However, 10 pg/mL IL1the approximate concentration secreted from PrP/SC (Fig. S8C) . Furthermore, 25(OH)D 3 induced dose-dependent growth inhibition of control PrP/SC and not IL1α shRNA PrP/SC (Fig. S8D) . This further supports the necessity for IL1α in the anti-proliferative Cancer cells have many phenotypic parallels to stem cells, and an increasing number of genotypic parallels are being made as well that have led to the cancer stem cell hypothesis. These have best been characterized in the hematopoietic stem cell system, with emphasis on the roles of Wnt, Notch, and β-catenin signaling (20) . Our array data revealed regulation of genes involved in these pathways as well as BMP and TGFβ signaling pathways (Table S6 and Tables S1-S4 ). These networks likely play roles in prostate stem cell maintenance and differentiation, and we are beginning to interrogate the impact of 1,25(OH) 2 D 3 signaling on these pathways. These experiments will provide insight into normal prostate development as well as the mechanism behind maintenance of prostate health by vitamin D, prompting rationale for an effective chemopreventative regimen.
These studies are among those that support a functional intersection between hormone and cytokine signaling. We found that IL1 is a critical component for vitamin D 3 signaling in the PrP/SC.
A previous report has shown that IL1 is not detected immunohistochemically in normal prostate cells in vivo, whereas IL1 is detected in benign prostatic hyperplasia (BPH) and in prostate cancer cells (44).
However, IL1 was detected at the edges of the cell membranes, so it was likely derived from the proinflammatory microenvironment associated with prostate cancer. The roles of endogenous IL1and its signaling components in these cell types are unknown. This is the first study reporting IL1in the normal adult prostate progenitor/stem cell, notably in response to 1,25(OH) 2 D 3 , and we have shown that IL1resides in the cytoplasm and nuclei of these cells.
We have identified a putative vitamin D response element (VDRE) upstream of the IL1coding region that aligns with known consensus VDREs (45-48) ( Table S7) 
